Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 19, Number 9—September 2013


Plasmodium falciparum Mutant Haplotype Infection during Pregnancy Associated with Reduced Birthweight, Tanzania

Daniel T. R. MinjaComments to Author , Christentze Schmiegelow, Bruno Mmbando, Stéphanie Boström, Mayke Oesterholt, Pamela Magistrado, Caroline Pehrson, Davis John, Ali Salanti, Adrian J.F. Luty1, Martha Lemnge, Thor Theander, John Lusingu, and Michael Alifrangis
Author affiliations: National Institute for Medical Research, Tanga Centre, Tanzania (D.T.R. Minja, B. Mmbando, P. Magistrado, M. Lemnge, J. Lusingu); University of Copenhagen, Copenhagen, Denmark (D.T.R. Minja, C. Schmiegelow, P. Magistrado, C. Pehrson, A. Salanti, T. Theander, J. Lusingu, M. Alifrangis); Wenner-Gren Institute, Stockholm, Sweden (S. Boström); Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands (M. Oesterholt, A.J.F. Luty); Kilimanjaro Christian Medical Centre, Moshi, Tanzania (D. John)

Main Article

Table 1

Stratification of Plasmodium falciparum mutant haplotypes among pregnant women, by exposure of the women to SP before infection, Korogwe District, Tanga Region, Tanzania, September 2008–October 2010*

Participant exposure to SP No. (%) women with infecting allelic haplotype
Quadruple or less, n = 5 Quintuple, n = 25 Sextuple, n = 24
Did not receive IPTp–SP (n = 28) 4 (14.3) 12 (42.9) 12 (42.9)
Received first dose of IPTp–SP (n = 18) 1 (5.6) 8 (44.4) 9 (50.0)
Received second dose of IPTp–SP (n = 8) 0 5 (62.5) 3 (37.5)
Had previous exposure to SP (n = 30)† 1 (3.3) 16 (53.0) 13 (43.0)

*SP, sulfadoxine–pyrimethamine; IPTp–SP, intermittent preventive treatment during pregnancy with SP.
†Received IPTp-SP or SP used as treatment for malaria before study inclusion.

Main Article

1Current affiliation: Mère et Enfant Face aux Infections Tropicales, Paris, France.